Abstract:The aim of this study was to assess the prognostic effect of AMH in frozen-thawed embryo transfers. A retrospective cohort study. All non-polycystic ovary patients who underwent their first frozen-thawed embryo transfers in our unit and had basal serum AMH evaluated between 2010 and 2015 were evaluated in this retrospective study. AMH was measured using the enzyme amplified two-site immunoassay (ELISA) provided by Beckman Coulter (AMH Gen II ELISA, Beckman Coulter). Individualized controlled ovarian hyper-stimulation (COH) protocols included long GnRH agonist, GnRH antagonist and minimal stimulation protocols, based on individual patient characteristics. When at least two follicles reached 18 mm in diameter, 5000-10,000 IU hCG (Ovidrel, Merck Serono) was adopted to achieve final follicular maturation and oocyte retrieval performed 32-36 hours later. Intracytoplasmic sperm injection was performed if the concentration of motile sperm was <1×106/mL, otherwise a conventional in vitro fertilization was used. Vitrification was performed for embryo freezing with the use of a Cryotop (Kitazato Corp.) device. Embryo transfer was operated under trans-vaginal sonography guidance. The primary outcome is Live birth rate, which was defined as rate of deliveries that resulted in at least one live born baby per transfer cycle. Chi-square and binary regression were used for data analysis. A P<0.05 indicated significant result. In total, 828 patients were included. We grouped them into three groups based on their baseline AMH concentration: low AMH group (<25th), middle AMH (25th- 75th) and high AMH level (>75th). The results showed lower AMH level was associated with significantly lower implantation rate (21.9% vs. 43.2% vs. 58.8%, P<0.001), clinical pregnancy rate (32.0% vs. 55.2% vs. 65.7%, P<0.001), live birth rate (21.8% vs. 43.6% vs. 52.7%, P<0.001) but higher miscarriage rate (31.8% vs. 17.5% vs. 15.4% P=0.014). After stratifying the patients into two age groups, being younger or older than 35 years, we still observed significant influence of AMH on outcomes in all patients in both age groups. Furthermore, serum AMH kept significant in multivariate analysis when adjusting covariates (i.e. age, FSH, AFC, endometrium thickness, endometrium preparation protocols, number of embryos transferred, etiology of infertility). The area under the curve (AUC) for serum AMH, age, AFC and FSH were 0.635, 0.634, 0.615 and 0.543 respectively, for predicting live birth. Our results demonstrated that baseline AMH was an independent predictive factor of live birth rate of frozen embryo transfers, irrespective of maternal age. It had only moderate predictive value on predicting live birth, superior to that of AFC and FSH.

Correlation analysis of baseline antimullerian hormone level and clinical pregnancy rate in advanced age patients with frozen-thawed embryo transfer

Clinical outcomes after elective double-embryo transfer in frozen cycles for women of advanced maternal age A retrospective cohort study

Clinical outcomes after elective double-embryo transfer in frozen cycles for women of advanced maternal age

Basal Serum Anti-Müllerian Hormone Level as a Predictor of Clinical Outcomes in Freezing-all Embryo Transfer Program

Anti-Müllerian hormone for prediction of ovarian response in Chinese infertile women undergoing IVF/ICSI cycles: a prospective, multi-centre, observational study

Correlation Analysis of Baseline Antimullerian Hormone Level and Live Birth Rate of FreshEmbryo Transfer Cycles and Frozen Embryo Transfer Cycles

IVF Outcomes of Women with Discrepancies Between Age and Serum Anti-Müllerian Hormone Levels.

Higher Serum AMH Level is Associated with Better Pregnancy Outcomes of IVF/ICSI Assisted Pregnancy in Infertile Patients under 35 Years Old.

Predictive value of AMH combined with age for IVF-ET outcomes

The Baseline Antimullerian Hormone (AMH) Level As an Independent Predictor of Live Birth Rate of Frozen-Thawed Embryo Transfers: a Multivariate Analysis of 828 Cycles

Analysis of cumulative outcomes and influencing factors of patients with discrepancies between age and AMH levels in the early follicular phase prolonged protocol

Serum Levels of Anti-Müllerian Hormone Influence Pregnancy Outcomes Associated with Gonadotropin-Releasing Hormone Antagonist Treatment: a Retrospective Cohort Study

Analysis of the Clinical Characteristics and Outcome of IVF Cycles in Advanced Age Women

High Anti-Mullerian Hormone Level Is Adversely Associated with Cumulative Live Birth Rates of Two Embryo Transfers after the First Initiated Cycle in Patients with Polycystic Ovary Syndrome

The Predictive Levels of Serum Anti-Müllerian Hormone and the Combined Index of the Number of Retrieved Oocytes and Good-Quality Embryos in Advanced-Age Infertile Women.

Anti-Müllerian Hormone in Guiding the Selection of a Freeze-All Versus a Fresh Embryo Transfer Strategy: a Cohort Study

High anti-Mullerian hormone levels might not reflect the likelihood of clinical pregnancy rate in IVF/ICSI treatment

Correlation of age and antimullerian hormone in assisted reproductive technology program outcome

Serum anti-Müllerian hormone levels are associated with early miscarriage in the IVF/ICSI fresh cycle

Low Anti-Müllerian Hormone Concentration is Associated with Increased Risk of Embryonic Aneuploidy in Women of Advanced Age.

The Role of Serum AMH and FF AMH in Predicting Pregnancy Outcome in the Fresh Cycle of IVF/ICSI: a Meta-Analysis.